Search Within

Population Sciences Research Program

  1. "Meeting abstract"
  2. "Robert Motzer"
  3. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (15)
Groups
  1. Department of Medicine (15)
  2. Epidemiology and Biostatistics (15)
  3. Genitourinary Oncology Service (15)
  4. Solid Tumor Oncology Division (15)
  5. Biostatistics Service (10)
  6. Surgery (8)

More Groups

People
  1. Robert Motzer (15)
  2. Maria Carlo (14)
  3. Martin Voss (13)
  4. Chung-Han Lee (12)
  5. Darren Feldman (9)
  6. Abraham Hakimi (8)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2021 (4)
  4. 2020 (3)
  5. 2019 (3)
  6. 2018 (3)
Publications
  1. Journal of Clinical Oncology (14)
  2. European Urology (1)
Publishers
  1. American Society of Clinical Oncology (14)
  2. Elsevier Science, Inc. (1)

Results (15)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Fitzgerald, K. N.; Voss, M. H.; Carlo, M. I.; Knezevic, A.; Peralta, L.; Chen, Y. B.; Zucker, M.; Lefkowitz, R. A.; Reznik, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Molecular profile and clinical outcomes of renal cell carcinoma brain metastases treated with stereotactic radiosurgery
    Meeting Abstract

    Ma, J.; del Balzo, L.; Khaleel, S. S.; Flynn, J.; Zhang, Z.; Voss, M. H.; Freeman, B.; Hakimi, A. A.; Lee, C. H.; Eichholz, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Voss, M. H.; Carlo, M. I.; Chen, Y. B.; Reznik, E.; Knezevic, A.; Lefkowitz, R. A.; Shapnik, N.; Tassone, D.; Dadoun, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Neutrophil-to-lymphocyte ratio in unclassified renal cell carcinoma is associated with clinical outcome and varies between genomic subgroups
    Meeting Abstract

    Marcon, J.; Di Natale, R. G.; Weng, S.; Ghanaat, M.; Silagy, A. W.; Mano, R.; Blum, K. A.; Attalla, K.; Reznik, E.; Carlo, M. I.; more...
    European Urology (2021)

    Fulltext@MSK | Save
  • Evaluation of germline genetic testing criteria in early-onset kidney cancer
    Meeting Abstract

    Truong, H.; Sheikh, R.; Kotecha, R.; Kemel, Y.; Khurram, A.; Reisz, P.; Lenis, A. T.; Joseph, V.; Mandelker, D.; Lee, C. H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A pilot study of preoperative nivolumab in high-risk nonmetastatic renal cell carcinoma
    Meeting Abstract

    Carlo, M. I.; Attalla, K.; Patil, S.; Murray, S. J.; Chen, Y. B.; Kotecha, R.; Durack, J. C.; Motzer, R. J.; Hakimi, A. A.; Voss, M. H.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Safety of weight-based dosing of nivolumab with or without ipilimumab by body mass index (BMI) stratified by sex across 14 CheckMate clinical trials
    Meeting Abstract

    McQuade, J. L.; Hammers, H. J.; Furberg, H.; Engert, A.; Andre, T.; Blumenschein, G.; Tannir, N. M.; Baron, A. D.; Larkin, J.; El-Khoueiry, A. B.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Impact of treatment line on outcomes with salvage ipilimumab plus nivolumab in metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Kotecha, R.; Lee, C. H.; Knezevic, A.; Shah, N. J.; Carlo, M. I.; Feldman, D. R.; Patil, S.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Prevalence and landscape of actionable genomic alterations in renal cell carcinoma
    Meeting Abstract

    Attalla, K.; DiNatale, R. G.; Reznik, E.; Fong, C.; Sanchez-Vega, F.; Silagy, A. W.; Weng, S.; Coleman, J.; Lee, C. H.; Carlo, M. I.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Association of body mass index (BMI) with clinical outcomes in 203 metastatic clear cell renal cell carcinoma (ccRCC) patients (pts) treated with immuno-oncology (IO) agents
    Meeting Abstract

    Ged, Y.; Lee, C. H.; Sanchez, A.; Duzgol, C.; Chaim, J.; Carlo, M. I.; Foster, A.; Akin, O.; Feldman, D. R.; Hakimi, A. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save